골다공증 치료제 시장 : 약물 유형, 투여 경로, 용도별 - 세계 전망(2025-2030년)

The Osteoporosis Drugs Market was valued at USD 8.32 billion in 2023, expected to reach USD 8.77 billion in 2024, and is projected to grow at a CAGR of 5.60%, to USD 12.19 billion by 2030.

The market for osteoporosis drugs is primarily focused on the treatment and prevention of osteoporosis, a condition characterized by reduced bone mass and increased fracture risk. This market encompasses a variety of pharmaceutical treatments, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH) analogs, and monoclonal antibodies. The necessity for these drugs is driven by the global aging population, notably among post-menopausal women, making the treatment of osteoporosis critical for improving quality of life and reducing healthcare costs related to fracture treatment. Application extends across hospitals, clinics, and home healthcare settings, targeting both therapeutic and preventive care. The end-users predominantly are older adults, particularly women beyond the menopausal age.

Key factors influencing market growth include increasing awareness and diagnosis rates, advances in drug formulation and administration, and supportive government healthcare policies. Opportunities also lie in emerging markets where healthcare infrastructure is rapidly improving. The development of drugs with fewer side effects and more convenient dosing regimens presents significant potential. However, significant limitations include high drug costs, stringent regulatory frameworks, and potential side effects that may impede patient adherence. Additionally, varying healthcare policies and reimbursement issues across regions pose challenges.

Innovation and research areas offering growth opportunities include the development of combination therapies, personalized medicine approaches, and the integration of telemedicine for remote patient management. Advances in biotechnology and gene therapy hold the promise of novel treatment platforms. The market exhibits a competitive nature with prominent players investing heavily in research to mitigate the existing drug side effects and improve efficacy. Companies are recommended to focus on strategic alliances and collaborations for R&D, exploring untapped regional markets, and emphasizing patient education programs to enhance market penetration. Addressing the existing limitations by optimizing drug delivery systems and enhancing drug formulation safety profiles should also be prioritized to bolster market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoporosis Drugs Market

The Osteoporosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising elderly population coupled with changing lifestyle habits impacting bone health
  • Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
• Market Restraints
  • Concerns over patent expiration of osteoporosis drugs
• Market Opportunities
  • Emerging product development and research activities in healthcare organizations
  • Proliferation in the research funding from various organizations
• Market Challenges
  • Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Osteoporosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoporosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoporosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoporosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoporosis Drugs Market

A detailed market share analysis in the Osteoporosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoporosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoporosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoporosis Drugs Market

A strategic analysis of the Osteoporosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoporosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alembic Pharmaceuticals Ltd., Alkem Laboratories Ltd., Amgen, Inc., Apotex Inc., Century Pharmaceuticals Ltd., Cipla Ltd., Cubit Healthcare, Dr. Reddy's Laboratories, Eli Lilly and Company, F.Hoffmann La Roche AG, GlaxoSmithKline PLC, Hetero Healthcare Ltd., Intas Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd., Merck & Co AG, Midas Pharma GmbH, Mylan N.V. by Viatris Inc., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Polpharma, Pulse Pharmaceuticals, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., and Vintage Labs Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoporosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and Selective Estrogen Inhibitors Modulator.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Application, market is studied across Primary Osteoporosis and Secondary Osteoporosis.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
    • 5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns over patent expiration of osteoporosis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging product development and research activities in healthcare organizations
    • 5.1.3.2. Proliferation in the research funding from various organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Osteoporosis Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Bisphosphonates
• 6.3. Calcitonin
• 6.4. Parathyroid Hormone Therapy
• 6.5. Rank Ligand Inhibitors
• 6.6. Selective Estrogen Inhibitors Modulator

7. Osteoporosis Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral

8. Osteoporosis Drugs Market, by Application

• 8.1. Introduction
• 8.2. Primary Osteoporosis
• 8.3. Secondary Osteoporosis

9. Americas Osteoporosis Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Osteoporosis Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Osteoporosis Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. New funding for osteoporosis research announced
  • 12.3.2. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
  • 12.3.3. FDA Clears Tymlos for Osteoporosis in Men
  • 12.3.4. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
  • 12.3.5. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
  • 12.3.6. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
  • 12.3.7. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
  • 12.3.8. Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan.
  • 12.3.9. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche
  • 12.3.10. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alembic Pharmaceuticals Ltd.
• 3. Alkem Laboratories Ltd.
• 4. Amgen, Inc.
• 5. Apotex Inc.
• 6. Century Pharmaceuticals Ltd.
• 7. Cipla Ltd.
• 8. Cubit Healthcare
• 9. Dr. Reddy's Laboratories
• 10. Eli Lilly and Company
• 11. F.Hoffmann La Roche AG
• 12. GlaxoSmithKline PLC
• 13. Hetero Healthcare Ltd.
• 14. Intas Pharmaceuticals Ltd
• 15. Macleods Pharmaceuticals Ltd.
• 16. Merck & Co AG
• 17. Midas Pharma GmbH
• 18. Mylan N.V. by Viatris Inc.
• 19. Natco Pharma Ltd.
• 20. Novartis AG
• 21. Pfizer Inc.
• 22. Polpharma
• 23. Pulse Pharmaceuticals
• 24. Steris Healthcare Pvt. Ltd.
• 25. Sun Pharmaceutical Industries Ltd
• 26. Taj Pharmaceuticals Ltd.
• 27. Teva Pharmaceutical Industries Ltd.
• 28. Vintage Labs Pvt. Ltd.